Congenital Hematological Disorder Completed Phase 3 Trials for Turoctocog alfa (DB09109)

Back to Congenital Hematological Disorder

Also known as: Congenital bleeding disorders / Congenital Bleeding Disorder / Congenital haematological disorder

IndicationStatusPhase
DBCOND0081791 (Congenital Hematological Disorder)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02938585Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia ATreatment
NCT01493778Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia ATreatment
NCT01138501Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia ATreatment
NCT00984126Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015Treatment
NCT00840086Safety and Efficacy of Turoctocog Alfa in Haemophilia A SubjectsTreatment